

mariposa HEALTH

(ABN 67 134 154 680)

Shareholder Newsletter: 28th January 2015

IMMINENT OFFER FOR US LISTING

At the end of November we advised shareholders of our path to US listing. We are pleased to advise that we are now finalising offer documents and anticipate them being dispatched to shareholders early February.

The approach is for Mariposa Health to be acquired by a company listed on a US OTC exchange, with subsequent trading on Nasdaq within a targeted period of a few months pending SEC requirements and market conditions.

In exchange for shares in Mariposa Health, shareholders will be offered shares in the vendor company pro rata to their holding in Mariposa. At closing of the transaction, Mariposa Health shareholders will own 80% and the Vendor shareholders 20% of the listed company. Initial financing is through a loan facility and will be complemented by capital raising within the OTC phase.

The Directors of the company each intend to take up the offer and upon receipt we ask shareholders to take up the offer with minimal delay.

Out-licensing discussions with a Chinese pharmaceutical company are continuing and we will keep shareholders informed as the transaction progresses.

We are approaching an important step in the growth of Mariposa Health and thank you for your continued support. You can expect to receive Offer documents shortly & we ask that shareholders read the information provided and respond with minimal delay. **Please advise us if you will be absent during early February or make alternate arrangements for execution of the Offer documents.** As always, please feel free to call me to discuss the above matters.

Yours faithfully,

Phillip Comans, PhD
Executive Chairman